Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jul 14, 2011

Premium

Title: Small Interfering RNAs Targeting Feline Herpes Virus

Patent Number: 7,977,321

Filed: Feb. 12, 2009

Lead Inventor: Stephen Kania, University of Tennessee

The patent, its abstract states, claims “polynucleotides, compositions thereof, and methods of treating feline herpes virus infections. In certain embodiments, the polynucleotides and compositions thereof can be used to reduce replication of feline herpes simplex virus 1 in vivo and/or in vitro.”


Title: siRNA Targeting TNF-Alpha

Patent Number: 7,977,471

Filed: Sept. 12, 2008

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to TNF-alpha.”


Title: RNA Interference-Mediated Inhibition of Myostatin Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,977,472

Filed: April 22, 2010

Lead Inventor: Leonid Beigelman, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating myostatin gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity by RNA interference using small nucleic acid molecules.”


Title: Compositions and Methods Using siRNA Molecules for Treatment of Gliomas

Application Number: 20110165227

Filed: March 16, 2011

Lead Inventor: Hai Yan, Duke University (Sirnaomics)

The invention, the patent application's abstract states, “provides small interfering RNA molecules, compositions containing the molecules, and methods of using the compositions to treat gliomas.”


Title: Methods for Producing Inducible and/or Repressible Expression Active Linear RNA Interference Cassettes and Inducible and/o Repressible Expression Active Linear Gene Cassettes and Their Uses

Application Number: 20110166042

Filed: May 25, 2009

Inventor: Khalid Khabar, King Faisal Specialist Hospital & Research Centre

The invention, the patent application's abstract states, relates to a “method for producing inducible and/or repressible expression active linear RNA interference constructs.” The method involves PCR amplification of a source polynucleotide comprised of an inhibitory RNA coding sequence of interest or of a DNA source comprising a promoter using a reverse primer comprising the inhibitory RNA coding sequence of interest.

The invention also relates to a method for producing inducible and/or repressible expression active linear gene constructs involving PCR amplification of a source expression polynucleotide comprising a promoter sequence and the DNA sequence of interest or PCR amplification using the DNA sequence as a template, the abstract adds.


Title: RNA Compositions for Modulating Immune Response

Application Number: 20110166198

Filed: April 8, 2009

Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

“This invention features modified iRNA agents that modulate an immune response, methods of making and identifying iRNA agents that modulate an immune response, and methods of using the iRNA agents to modulate an immune response,” the patent application's abstract states.


Title: RNAi Compound Targeted to Thrombospondin-1 and Applications Thereof

Application Number: 20110166199

Filed: Jan. 6, 2011

Lead Inventor: Ming-Derg Lai, National Cheng Kung University

The invention, the patent application's abstract states, “relates to an RNAi compound and an expression plasmid for inhibiting expression of thrombospondin-1, which comprises a target sequence selected from [the] thrombospondin-1 gene. The ... invention also relates to a pharmaceutical composition comprising the RNAi compound and applications thereof.

“The RNAi compound can reduce the expression of thrombospondin-1 to activate immune responses,” it adds. “In addition, the ... invention also discloses that an RNAi compound targeted to thrombospondin-1 gene can delay tumor progression.”


Title: Methods of Using miR-210 as a Biomarker for Hypoxia and as a Therapeutic Agent for Treating Cancer

Application Number: 20110166200

Filed: April 16, 2009

Lead Inventor: Zhan Zhang, Merck

The invention “provides compositions and methods for predicting the hypoxia response in tumor cells, methods for predicting the likelihood of cancer metastasis, and methods for inhibiting tumor cell proliferation using a microRNA comprising miR-210,” the patent application's abstract states.


Title: miRNAs as Therapeutic Targets in Cancer

Application Number: 20110166201

Filed: June 5, 2009

Lead Inventor: Jingfang Ju, Stony Brook University Medical Center

“The invention relates to the application of miR-192 and miR-215,” the patent application's abstract states. “Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase and thymidylate synthase. Particularly, up-regulation of these miRNAs reduces cellular proliferation. ... Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.”

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.